Govt supports TechInvention Lifecare for development of 16-valent Pneumococcal Conjugate Vaccine – BioSpectrum India

Home Technology Govt supports TechInvention Lifecare for development of 16-valent Pneumococcal Conjugate Vaccine – BioSpectrum India
Govt supports TechInvention Lifecare for development of 16-valent Pneumococcal Conjugate Vaccine – BioSpectrum India


November 21, 2025 | Friday | News

image credit- pib
The Technology Development Board (TDB), Department of Science & Technology, Government of India, has sanctioned financial support to Mumbai-based startup TechInvention Lifecare for the establishment of a commercial-scale cGMP facility for the production of an indigenously developed 16-valent Pneumococcal Conjugate Vaccine (PCV-16).
The supported project aims to strengthen India’s capability in next-generation conjugate vaccines and reduce long-term dependence on imported products through domestic innovation and manufacturing.
The PCV-16 technology is built on a strategically selected panel of 16 pneumococcal serotypes, representing strains most associated with invasive pneumococcal disease (IPD), antimicrobial resistance and high fatality risks in India and other low- and middle-income countries. While 13 serotypes overlap with existing global PCV platforms, the inclusion of three emerging serotypes—12F, 15A and 22F—provides broader coverage against evolving non-vaccine serogroups, reinforcing the public-health value of this indigenous approach.
The project reflects a science-based re-evaluation of serotype prioritisation, designed to support cost-effective immunisation for children, the elderly and vulnerable populations. The early upstream and downstream development was conducted at TechInvention’s BSL-2 facility within the BSC BioNEST Bio-Incubator, RCB Faridabad, and later advanced to the company’s GMP-aligned high-containment R&D centre, ‘HORIZON’, in Navi Mumbai. An Indian patent has been filed to safeguard the unique serotype design and process innovations.
With TDB’s support, the project will now move towards full-scale cGMP manufacturing, ensuring that advanced conjugate vaccine technologies are developed, validated and commercialised within the country. The initiative is expected to significantly bolster India’s self-reliance in critical vaccines, enhance domestic biomanufacturing capacity and create pathways for future multivalent platforms.
 

Is India Inching Towards API Self-Reliance?

Ashirwad Bungalow, First floor,
36/A/2, S.No. 270, Pallod Farms,
Near Bank of Baroda, Baner Road,
Pune, Maharashtra, India 411045

[email protected]
+91-9579069369
Copyright 2026 MM Activ Sci-Tech Communications. All Rights Reserved.




Forgot your password?

First Name should not be empty!
Last Name should not be empty!
Email address should not be empty!
Show Password should not be empty!
Show Confirm Password should not be empty!
Newsletter
E-magazine
Biospectrum Infomercial
Bio Resource
I accept the terms & conditions & Privacy policy



Back to log-in

source

Leave a Reply

Your email address will not be published.